Brought to you by 
AZ to pay £567mm for Cambridge Antibody Technology
17 May 2006
Executive Summary
AstraZeneca has offered to pay £13.20 ($24.96) per share (a 72% premium to the market average) to buy the remaining 80% of Cambridge Antibody Technology Group PLC that it does not already own. It is effectively paying £567mm for the remaining stake, and valuing all of CAT at £702mm, about 4 times the company's 2005 revenues of £194mm.
Deal Industry
- Pharmaceuticals
-
Biotechnology
-
Large Molecule
- Antibodies
-
Large Molecule
Deal Status
- Final
Deal Type
-
Acquisition
- Partial Acquisition
- Payment Includes Cash
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
AZ to pay £567mm for Cambridge Antibody Technology
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice